Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a

Journal of Neurology

Volumn 257, Issue 4, 2010, Pages 584-589

  Jongen, Peter Joseph ^a   Sindic, Christian ^b   Carton, Herwig ^c   Zwanikken, Cees ^d   Lemmens, Wim ^e   Borm, George ^e  

^a MS4 Research Institute   (Netherlands)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Multiple Sclerosis Centre Nijmegen   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Disability; Health related quality of life; Interferon beta; Intramuscular; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; EUROPE; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 77951255196     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5378-x     Document Type: Article

References (16)

1. JH Arnoldus J Killestein LE Pfennings B Jelles BM Uitdehaag CH Polman 2000 Quality of life during the first 6 months of interferon-beta treatment in patients with MS Mult Scler 6 338 342 1:STN:280:DC%2BD3crhtF2luw%3D%3D 11064444
2. JA Cohen JS Fischer DM Bolibrush AJ Jak JE Kniker LA Mertz, et al. 2000 Intrarater and interrater reliability of the MS functional composite outcome measure Neurology 54 802 806 1:STN:280:DC%2BD3c7lt1yhtw%3D%3D 10690966
3. JA Cohen GR Cutter JS Fischer AD Goodman FR Heidenreich AJ Jak, et al. 2001 Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial Arch Neurol 58 961 967 10.1001/archneur.58.6.961 1:STN:280:DC%2BD3MzntlKgug%3D%3D 11405811
4. G Cutter M Baier RA Rudick DL Cookfair JS Fischer J Petkau, et al. 1999 Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain 122 871 882 10.1093/brain/122.5.871 10355672 (Pubitemid 29219261)
5. WM Hopman H Coo CM Edgar EV McBride AG Day DG Brunet 2007 Factors associated with health-related quality of life in multiple sclerosis Can J Neurol Sci 34 160 166 17598592 (Pubitemid 47000117)
6. International Conference on Harmonisation (1997) Federal Register 62:52239-52245
7. O Lily E McFadden E Hensor M Johnson H Ford 2006 Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment Mult Scler 12 808 813 10.1177/1352458506070946 1:STN:280:DC%2BD2s%2FlvVyksQ%3D%3D 17263011 (Pubitemid 46111775)
8. DM Miller RA Rudick M Baier G Cutter DS Dougherty B Weinstock-Guttman, et al. 2003 Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis Mult Scler 9 1 5 10.1191/ 1352458503ms888oa 12617260 (Pubitemid 36253688)
9. DM Miller RA Rudick G Cutter M Baier JS Fischer 2000 Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life Arch Neurol 57 1319 1324 10.1001/archneur.57.9. 1319 1:STN:280:DC%2BD3cvnsFOktg%3D%3D 10987899
10. S Ozakbas I Cagiran B Ormeci E Idiman 2004 Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after relapses in patients with multiple sclerosis J Neurol Sci 218 1 2 10.1016/j.jns.2003.09.015 (Pubitemid 38169388)
11. N Pfaffenberger K-P Pfeiffer M Deibl S Hoefer V Guenther H Ulmer 2006 Association of factors influencing health-related quality of life in MS Acta Neurol Scand 114 102 108 10.1111/j.1600-0404.2006.00659.x 1:STN:280: DC%2BD28vktlaqsA%3D%3D 16867032 (Pubitemid 44034257)
12. GP Rice J Oger P Duquette GS Francis M Belanger S Laplante, et al. 1999 Treatment with interferon beta-1b improves quality of life in multiple sclerosis Can J Neurol Sci 26 276 282 1:STN:280:DC%2BD3c%2FivV2msA%3D%3D 10563212 (Pubitemid 29522812)
13. IL Simone A Ceccarelli C Tortorella A Bellacosa F Pellegrini I Plasmati, et al. 2006 Influence of Interferon beta treatment on quality of life in multiple sclerosis patients Health Qual Life Outcomes 12 96 10.1186/1477-7525-4- 96 (Pubitemid 46017466)
14. P Vermersch J de Seze B Delisse S Lemaire T Stojkovic 2002 Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment Mult Scler 8 377 381 10.1191/1352458502ms826oa 1:CAS:528:DC%2BD38XnvVWjtbo%3D 12356203
15. BG Vickrey RD Hays R Harooni LW Myers GW Ellison 1995 A health-related quality of life measure for multiple sclerosis Qual Life Red 4 187 206 10.1007/BF02260859 1:STN:280:DyaK2MzjvVWqtg%3D%3D
16. R Zivadinov M Zorzon MA Tommasi D Nasuelli M Bernardi L Monti-Bragadin, et al. 2003 A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a J Neurol Sci 216 113 118 10.1016/S0022-510X(03)00225-9 1:CAS:528:DC%2BD3sXos1Klsrk%3D 14607312 (Pubitemid 37371875)